Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy

British Journal of Pharmacology

Volumn 171, Issue 8, 2014, Pages 2080-2090

  Fillmore, N ^a   Mori, J ^a   Lopaschuk, G D ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

glucose oxidation; malonyl CoA; PPAR ; pyruvate dehydrogenase

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADENOSINE TRIPHOSPHATE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETOMOXIR; FIBRIC ACID DERIVATIVE; MALONYL COENZYME A DECARBOXYLASE; PERHEXILINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; TRIMETAZIDINE; FATTY ACID;

AEROBIC METABOLISM; CITRIC ACID CYCLE; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DISEASE EXACERBATION; ENERGY METABOLISM; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; GLUCOSE OXIDATION; GLYCOLYSIS; HEART DISEASE; HEART FAILURE; HEART HYPERTROPHY; HEART MUSCLE ISCHEMIA; HEART VENTRICLE OVERLOAD; HUMAN; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPID STORAGE; LIPOTOXICITY; MITOCHONDRIAL RESPIRATION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXYGEN CONSUMPTION; PERIPHERAL EDEMA; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; DIABETIC CARDIOMYOPATHIES; DRUG EFFECTS; HEART MUSCLE; METABOLISM; MITOCHONDRION; MOLECULARLY TARGETED THERAPY; MYOCARDIAL ISCHEMIA; OXIDATION REDUCTION REACTION; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES;

DIABETIC CARDIOMYOPATHIES; ENERGY METABOLISM; FATTY ACIDS; HEART FAILURE; HUMANS; MITOCHONDRIA; MOLECULAR TARGETED THERAPY; MYOCARDIAL ISCHEMIA; MYOCARDIUM; OXIDATION-REDUCTION;

EID: 84897394439     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12475     Document Type: Review

References (86)

1. el Alaoui-Talibi Z, Landormy S, Loireau A, Moravec J, (1992). Fatty acid oxidation and mechanical performance of volume-overloaded rat hearts. Am J Physiol Heart Circ Physiol 262: H1068-H1074.
2. Allard MF, Schonekess BO, Henning SL, English DR, Lopaschuk GD, (1994). Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts. Am J Physiol Heart Circ Physiol 267: H742-H750.
3. Axelsen LN, Keung W, Pedersen HD, Meier E, Riber D, Kjolbye AL, et al. (2012). Glucagon and a glucagon-GLP-1 dual-agonist increases cardiac performance with different metabolic effects in insulin-resistant hearts. Br J Pharmacol 165: 2736-2748.
4. Beer M, Seyfarth T, Sandstede J, Landschutz W, Lipke C, Kostler H, et al. (2002). Absolute concentrations of high-energy phosphate metabolites in normal, hypertrophied, and failing human myocardium measured noninvasively with (31)P-SLOOP magnetic resonance spectroscopy. J Am Coll Cardiol 40: 1267-1274.
5. Berthiaume JM, Bray MS, McElfresh TA, Chen X, Azam S, Young ME, et al. (2010). The myocardial contractile response to physiological stress improves with high saturated fat feeding in heart failure. Am J Physiol Heart Circ Physiol 299: H410-H421.
6. Berthiaume JM, Young ME, Chen X, McElfresh TA, Yu X, Chandler MP, (2012). Normalizing the metabolic phenotype after myocardial infarction: impact of subchronic high fat feeding. J Mol Cell Cardiol 53: 125-133.
7. Buchanan J, Mazumder PK, Hu P, Chakrabarti G, Roberts MW, Yun UJ, et al. (2005). Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 146: 5341-5349.
8. Burkart EM, Sambandam N, Han X, Gross RW, Courtois M, Gierasch CM, et al. (2007). Nuclear receptors PPARbeta/delta and PPARalpha direct distinct metabolic regulatory programs in the mouse heart. J Clin Invest 117: 3930-3939.
9. Carley AN, Severson DL, (2005). Fatty acid metabolism is enhanced in type 2 diabetic hearts. Biochim Biophys Acta 1734: 112-126.
10. Carley AN, Atkinson LL, Bonen A, Harper ME, Kunnathu S, Lopaschuk GD, et al. (2007). Mechanisms responsible for enhanced fatty acid utilization by perfused hearts from type 2 diabetic db/db mice. Arch Physiol Biochem 113: 65-75.
11. Chabowski A, Coort SL, Calles-Escandon J, Tandon NN, Glatz JF, Luiken JJ, et al. (2005). The subcellular compartmentation of fatty acid transporters is regulated differently by insulin and by AICAR. FEBS Lett 579: 2428-2432.
12. Cheng JF, Huang Y, Penuliar R, Nishimoto M, Liu L, Arrhenius T, et al. (2006). Discovery of potent and orally available malonyl-CoA decarboxylase inhibitors as cardioprotective agents. J Med Chem 49: 4055-4058.
13. Chiu HC, Kovacs A, Ford DA, Hsu FF, Garcia R, Herrero P, et al. (2001). A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest 107: 813-822.
14. Conway MA, Allis J, Ouwerkerk R, Niioka T, Rajagopalan B, Radda GK, (1991). Detection of low phosphocreatine to ATP ratio in failing hypertrophied human myocardium by 31P magnetic resonance spectroscopy. Lancet 338: 973-976.
15. Cook WS, Yeldandi AV, Rao MS, Hashimoto T, Reddy JK, (2000). Less extrahepatic induction of fatty acid beta-oxidation enzymes by PPAR alpha. Biochem Biophys Res Commun 278: 250-257.
16. Coort SL, Hasselbaink DM, Koonen DP, Willems J, Coumans WA, Chabowski A, et al. (2004). Enhanced sarcolemmal FAT/CD36 content and triacylglycerol storage in cardiac myocytes from obese zucker rats. Diabetes 53: 1655-1663.
17. Dai DF, Johnson SC, Villarin JJ, Chin MT, Nieves-Cintron M, Chen T, et al. (2011). Mitochondrial oxidative stress mediates angiotensin II-induced cardiac hypertrophy and Galphaq overexpression-induced heart failure. Circ Res 108: 837-846.
18. Daniels A, van Bilsen M, Janssen BJ, Brouns AE, Cleutjens JP, Roemen TH, et al. (2010). Impaired cardiac functional reserve in type 2 diabetic db/db mice is associated with metabolic, but not structural, remodelling. Acta Physiol (Oxf) 200: 11-22.
19. Degens H, de Brouwer KF, Gilde AJ, Lindhout M, Willemsen PH, Janssen BJ, et al. (2006). Cardiac fatty acid metabolism is preserved in the compensated hypertrophic rat heart. Basic Res Cardiol 101: 17-26.
20. Dennis SC, Gevers W, Opie LH, (1991). Protons in ischemia: where do they come from; where do they go to? J Mol Cell Cardiol 23: 1077-1086.
21. Donnelly R, Emslie-Smith AM, Gardner ID, Morris AD, (2000). ABC of arterial and venous disease: vascular complications of diabetes. BMJ 320: 1062-1066.
22. Dormandy JA, Charbonnel B, Eckland DJA, Erdmann E, Massi-Benedetti M, Moules IK, et al. (2005). Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366: 1279-1289.
23. Dyck JR, Cheng JF, Stanley WC, Barr R, Chandler MP, Brown S, et al. (2004). Malonyl coenzyme a decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation. Circ Res 94: e78-e84.
24. Eaton S, Middleton B, Bartlett K, (1998). Control of mitochondrial beta-oxidation: sensitivity of the trifunctional protein to [NAD+]/[NADH] and [acetyl-CoA]/[CoA]. Biochim Biophys Acta 1429: 230-238.
25. Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, et al. (2002). The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest 109: 121-130.
26. Folmes CD, Sowah D, Clanachan AS, Lopaschuk GD, (2009). High rates of residual fatty acid oxidation during mild ischemia decrease cardiac work and efficiency. J Mol Cell Cardiol 47: 142-148.
27. Fragasso G, Palloshi A, Puccetti P, Silipigni C, Rossodivita A, Pala M, et al. (2006a). A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol 48: 992-998.
28. Fragasso G, Perseghin G, De Cobelli F, Esposito A, Palloshi A, Lattuada G, et al. (2006b). Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J 27: 942-948.
29. Herrero P, Peterson LR, McGill JB, Matthew S, Lesniak D, Dence C, et al. (2006). Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus. J Am Coll Cardiol 47: 598-604.
30. How OJ, Larsen TS, Hafstad AD, Khalid A, Myhre ES, Murray AJ, et al. (2007). Rosiglitazone treatment improves cardiac efficiency in hearts from diabetic mice. Arch Physiol Biochem 113: 211-220.
31. Jaswal JS, Keung W, Wang W, Ussher JR, Lopaschuk GD, (2011). Targeting fatty acid and carbohydrate oxidation-A novel therapeutic intervention in the ischemic and failing heart. Biochim Biophys Acta 1813: 1333-1350.
32. Kantor PF, Lucien A, Kozak R, Lopaschuk GD, (2000). The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 86: 580-588.
33. Kato T, Niizuma S, Inuzuka Y, Kawashima T, Okuda J, Tamaki Y, et al. (2010). Analysis of metabolic remodeling in compensated left ventricular hypertrophy and heart failure. Circ Heart Fail 3: 420-430.
34. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. (2005). Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366: 1849-1861.
35. Keller A, Rouzeau JD, Farhadian F, Wisnewsky C, Marotte F, Lamande N, et al. (1995). Differential expression of alpha- and beta-enolase genes during rat heart development and hypertrophy. Am J Physiol Heart Circ Physiol 269: H1843-H1851.
36. Kolwicz SC, Jr, Olson DP, Marney LC, Garcia-Menendez L, Synovec RE, Tian R, (2012). Cardiac-specific deletion of acetyl CoA carboxylase 2 prevents metabolic remodeling during pressure-overload hypertrophy. Circ Res 111: 728-738.
37. Kudo N, Barr AJ, Barr RL, Desai S, Lopaschuk GD, (1995). High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5'-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J Biol Chem 270: 17513-17520.
38. Lei B, Lionetti V, Young ME, Chandler MP, d'Agostino C, Kang E, et al. (2004). Paradoxical downregulation of the glucose oxidation pathway despite enhanced flux in severe heart failure. J Mol Cell Cardiol 36: 567-576.
39. Lindenfeld J, Masoudi FA, (2007). Fluid retention with thiazolidinediones: does the mechanism influence the outcome? J Am Coll Cardiol 49: 1705-1707.
40. Liu Q, Docherty JC, Rendell JCT, Clanachan AS, Lopaschuk GD, (2002). High levels of fatty acids delay the recovery of intracellular pH and cardiac efficiency in post-ischemic hearts by inhibiting glucose oxidation. J Am Coll Cardiol 39: 718-725.
41. Lopaschuk GD, Tsang H, (1987). Metabolism of palmitate in isolated working hearts from spontaneously diabetic 'BB' Wistar rats. Circ Res 61: 853-858.
42. Lopaschuk GD, Barr R, Thomas PD, Dyck JR, (2003). Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase. Circ Res 93: e33-e37.
43. Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC, (2010). Myocardial fatty acid metabolism in health and disease. Physiol Rev 90: 207-258.
44. Luiken JJ, Arumugam Y, Dyck DJ, Bell RC, Pelsers MM, Turcotte LP, et al. (2001). Increased rates of fatty acid uptake and plasmalemmal fatty acid transporters in obese Zucker rats. J Biol Chem 276: 40567-40573.
45. McGarry JD, Mannaerts GP, Foster DW, (1977). A possible role for malonyl-CoA in the regulation of hepatic fatty acid oxidation and ketogenesis. J Clin Invest 60: 265-270.
46. McGarry JD, Leatherman GF, Foster DW, (1978). Carnitine palmitoyltransferase I. The site of inhibition of hepatic fatty acid oxidation by malonyl-CoA. J Biol Chem 253: 4128-4136.
47. Mazumder PK, O'Neill BT, Roberts MW, Buchanan J, Yun UJ, Cooksey RC, et al. (2004). Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob/ob mouse hearts. Diabetes 53: 2366-2374.
48. Mori J, Basu R, McLean BA, Das SK, Zhang L, Patel VB, et al. (2012). Agonist-induced hypertrophy and diastolic dysfunction are associated with selective reduction in glucose oxidation: a metabolic contribution to heart failure with normal ejection fraction. Circ Heart Fail 5: 493-503.
49. Mori J, Alrob OA, Wagg CS, Harris RA, Lopaschuk GD, Oudit GY, (2013a). Ang II causes insulin resistance and induces cardiac metabolic switch and inefficiency: a critical role of PDK4. Am J Physiol Heart Circ Physiol 304: H1103-H1113.
50. Mori J, Zhang L, Oudit GY, Lopaschuk GD, (2013b). Impact of the renin-angiotensin system on cardiac energy metabolism in heart failure. J Mol Cell Cardiol 63: 98-106.
51. Morissette MR, Howes AL, Zhang T, Heller Brown J, (2003). Upregulation of GLUT1 expression is necessary for hypertrophy and survival of neonatal rat cardiomyocytes. J Mol Cell Cardiol 35: 1217-1227.
52. Nascimben L, Friedrich J, Liao R, Pauletto P, Pessina AC, Ingwall JS, (1995). Enalapril treatment increases cardiac performance and energy reserve via the creatine kinase reaction in myocardium of Syrian myopathic hamsters with advanced heart failure. Circulation 91: 1824-1833.
53. Neubauer S, Remkes H, Spindler M, Horn M, Wiesmann F, Prestle J, et al. (1999). Downregulation of the Na+-creatine cotransporter in failing human myocardium and in experimental heart failure. Circulation 100: 1847-1850.
54. Olowe Y, Schulz H, (1980). Regulation of thiolases from pig heart. Control of fatty acid oxidation in heart. Eur J Biochem 109: 425-429.
55. Onay-Besikci A, Guner S, Arioglu E, Ozakca I, Ozcelikay AT, Altan VM, (2007). The effects of chronic trimetazidine treatment on mechanical function and fatty acid oxidation in diabetic rat hearts. Can J Physiol Pharmacol 85: 527-535.
56. Paulson DJ, Ward KM, Shug AL, (1984). Malonyl CoA inhibition of carnitine palmityltransferase in rat heart mitochondria. FEBS Lett 176: 381-384.
57. Pellieux C, Aasum E, Larsen TS, Montessuit C, Papageorgiou I, Pedrazzini T, et al. (2006). Overexpression of angiotensinogen in the myocardium induces downregulation of the fatty acid oxidation pathway. J Mol Cell Cardiol 41: 459-466.
58. Pellieux C, Montessuit C, Papageorgiou I, Lerch R, (2009). Angiotensin II downregulates the fatty acid oxidation pathway in adult rat cardiomyocytes via release of tumour necrosis factor-alpha. Cardiovasc Res 82: 341-350.
59. Peterson LR, Herrero P, Schechtman KB, Racette SB, Waggoner AD, Kisrieva-Ware Z, et al. (2004). Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation 109: 2191-2196.
60. Peterson LR, Saeed IM, McGill JB, Herrero P, Schechtman KB, Gunawardena R, et al. (2012). Sex and type 2 diabetes: obesity-independent effects on left ventricular substrate metabolism and relaxation in humans. Obesity 20: 802-810.
61. Planavila A, Laguna JC, Vázquez-Carrera M, (2005). Nuclear factor-κB activation leads to down-regulation of fatty acid oxidation during cardiac hypertrophy. J Biol Chem 280: 17464-17471.
62. Randle PJ, Garland PB, Hales CN, Newsholme EA, (1963). The glucose fatty-acid cycle its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 281: 785-789.
63. Randle PJ, England PJ, Denton RM, (1970). Control of the tricarboxylate cycle and its interactions with glycolysis during acetate utilization in rat heart. Biochem J 117: 677-695.
64. Rijzewijk LJ, van der Meer RW, Lamb HJ, de Jong HW, Lubberink M, Romijn JA, et al. (2009). Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. J Am Coll Cardiol 54: 1524-1532.
65. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. (1999). Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341: 410-418.
66. Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, et al. (2002). Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 162: 2597-2604.
67. Saeedi R, Grist M, Wambolt RB, Bescond-Jacquet A, Lucien A, Allard MF, (2005). Trimetazidine normalizes postischemic function of hypertrophied rat hearts. J Pharmacol Exp Ther 314: 446-454.
68. Schoonjans K, Staels B, Grimaldi P, Auwerx J, (1993). Acyl-CoA synthetase mRNA expression is controlled by fibric-acid derivatives, feeding and liver proliferation. Eur J Biochem 216: 615-622.
69. Sharma V, Dhillon P, Wambolt R, Parsons H, Brownsey R, Allard MF, et al. (2008). Metoprolol improves cardiac function and modulates cardiac metabolism in the streptozotocin-diabetic rat. Am J Physiol Heart Circ Physiol 294: H1609-H1620.
70. Shearer J, Fueger PT, Wang Z, Bracy DP, Wasserman DH, Rottman JN, (2008). Metabolic implications of reduced heart-type fatty acid binding protein in insulin resistant cardiac muscle. Biochim Biophys Acta 1782: 586-592.
71. Sidell RJ, Cole MA, Draper NJ, Desrois M, Buckingham RE, Clarke K, (2002). Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the zucker Fatty rat heart. Diabetes 51: 1110-1117.
72. Stanley WC, Morgan EE, Huang H, McElfresh TA, Sterk JP, Okere IC, et al. (2005). Malonyl-CoA decarboxylase inhibition suppresses fatty acid oxidation and reduces lactate production during demand-induced ischemia. Am J Physiol Heart Circ Physiol 289: H2304-H2309.
73. Sugden MC, Holness MJ, (2003). Recent advances in mechanisms regulating glucose oxidation at the level of the pyruvate dehydrogenase complex by PDKs. Am J Physiol Endocrinol Metab 284: E855-E862.
74. Tian R, Nascimben L, Kaddurah-Daouk R, Ingwall JS, (1996). Depletion of energy reserve via the creatine kinase reaction during the evolution of heart failure in cardiomyopathic hamsters. J Mol Cell Cardiol 28: 755-765.
75. Tuunanen H, Engblom E, Naum A, Nagren K, Hesse B, Airaksinen KE, et al. (2006). Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure. Circulation 114: 2130-2137.
76. Ussher JR, Folmes CD, Keung W, Fillmore N, Jaswal JS, Cadete VJ, et al. (2012a). Inhibition of serine palmitoyl transferase I reduces cardiac ceramide levels and increases glycolysis rates following diet-induced insulin resistance. PLoS ONE 7: e37703.
77. Ussher JR, Wang W, Gandhi M, Keung W, Samokhvalov V, Oka T, et al. (2012b). Stimulation of glucose oxidation protects against acute myocardial infarction and reperfusion injury. Cardiovasc Res 94: 359-369.
78. Yagyu H, Chen G, Yokoyama M, Hirata K, Augustus A, Kako Y, et al. (2003). Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. J Clin Invest 111: 419-426.
79. Yang Q, Li Y, (2007). Roles of PPARs on regulating myocardial energy and lipid homeostasis. J Mol Med 85: 697-706.
80. Yue T-L, Bao W, Jucker BM, Gu J-L, Romanic AM, Brown PJ, et al. (2003). Activation of peroxisome proliferator-activated receptor-alpha protects the heart from ischemia/reperfusion injury. Circulation 108: 2393-2399.
81. Yue T-L, Bao W, Gu J-L, Cui J, Tao L, Ma X-L, et al. (2005). Rosiglitazone treatment in zucker diabetic fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion- induced myocardial injury. Diabetes 54: 554-562.
82. Zhabyeyev P, Gandhi M, Mori J, Basu R, Kassiri Z, Clanachan A, et al. (2013). Pressure-overload-induced heart failure induces a selective reduction in glucose oxidation at physiological afterload. Cardiovasc Res 97: 676-685.
83. Zhang L, Keung W, Samokhvalov V, Wang W, Lopaschuk GD, (2010). Role of fatty acid uptake and fatty acid beta-oxidation in mediating insulin resistance in heart and skeletal muscle. Biochim Biophys Acta 1801: 1-22.
84. Zhang L, Ussher JR, Oka T, Cadete VJ, Wagg C, Lopaschuk GD, (2011). Cardiac diacylglycerol accumulation in high fat-fed mice is associated with impaired insulin-stimulated glucose oxidation. Cardiovasc Res 89: 148-156.
85. Zhang L, Jaswal JS, Ussher JR, Sankaralingam S, Wagg C, Zaugg M, et al. (2013). Cardiac insulin resistance and decreased mitochondrial energy production precede the development of systolic heart failure following pressure overload hypertrophy. Circ Heart Fail 6: 1039-1048.
86. Zhu P, Lu L, Xu Y, Schwartz GG, (2000). Troglitazone improves recovery of left ventricular function after regional ischemia in pigs. Circulation 101: 1165-1171.